SOURCE: NeuroInvestment

May 05, 2005 14:18 ET

Epilepsy Programs Reviewed by NeuroInvestment

RYE, NH -- (MARKET WIRE) -- May 5, 2005 -- NI Research today announced the release of the May issue of NeuroInvestment, reviewing the development of novel therapies for the treatment of epilepsy. In the United States, two million individuals have epilepsy, and the worldwide sales of antiepileptic drugs is approximately $8 billion, though much of that is for other indications. While there is a large number of medications available for epilepsy, and approximately 70% of patients are well-controlled vis-a-vis seizures, a plethora of side effects and drug interactions bedevil these patients. The May issue of NeuroInvestment reviews current major themes in epilepsy research, and a range of therapeutics under development are assessed. Some of the programs included in this review are from UCB, Newron, Ivax, Valeant, Schwarz, D-Pharm, and Ovation. The May issue also reports on developments in the CNS field, including setbacks for Prana, Memory Pharmaceuticals and Neurochem. On the plus side, Cortex (AMEX: COR) obtained impressive results from a Phase IIa trial in sleep deprivation, setting the stage for CX717's development as a competitor to Cephalon's Provigil, which itself made progress in beating back the spectre of generics. Just after the publication of the May issue, AstraZeneca and Renovis (NASDAQ: RNVS) announced surprisingly strong primary endpoint findings for Cerovive in its first Phase III stroke trial. If the second Phase III confirms these positive effects upon disability, Cerovive will become the first approved neuroprotectant drug.

Recent issues of NI have reviewed spinal cord injury, ALS, schizophrenia, and epilepsy. The forthcoming June issue will assess the ADHD field.

NeuroInvestment Subscription Rates: Pharmaceutical: 3-month trial $350, 1 year $1250, 2 years $2280 Individual Investor: 3-month trial $150, 1 year $450, 2 years $800.

Outside the US/Canada add $40 per year for hardcopy airmail. For combined hardcopy and email delivery, add $150 per year ($50 for individuals).

Information about NeuroInvestment's Institutional Edition is available on request.

NI Research is the leading publisher of independent research regarding the CNS therapeutics area. NI has published NeuroInvestment since 1995. NI Research also publishes the annual Private CNS Company Review, whose 2005 edition is in preparation; and provides product licensing consultation and custom research for large and small pharmaceutical firms.

Contact Information